Research item on how variations in KRAS-wild status impact Cetuximab effectiveness

coloCan

www.biomedcentral.com/1471-2407/13/169/abstract

(there's more info in the link attached but this is all rather "technical")

steved

Interesting

Increasing thespecificity of chemo would be great. Preventing people who won't benefit from a drug having to be exposed to it will reduce the harm associated with them. 

Steve

coloCan

steved said:

Interesting

Increasing thespecificity of chemo would be great. Preventing people who won't benefit from a drug having to be exposed to it will reduce the harm associated with them. 

Steve

From one steve to another: there's a little more of such info

here

www.onclive.com/publications/obtn/2013/march-2013/molecular-pathways-pathways-and-more-pathways/1 

Tho EGFR and KRAS get the most attention. (Hope with each passing day you feel better)

 

steved

coloCan said:

From one steve to another: there's a little more of such info

here

www.onclive.com/publications/obtn/2013/march-2013/molecular-pathways-pathways-and-more-pathways/1 

Tho EGFR and KRAS get the most attention. (Hope with each passing day you feel better)

 

Is practice keeping up?

Meeting with oncologist next week and will ask if testing anything more than kras in practice yet.

Slowly recovery moving forward here, thanks for your continued academic stimulation,

Steve

coloCan

steved said:

Is practice keeping up?

Meeting with oncologist next week and will ask if testing anything more than kras in practice yet.

Slowly recovery moving forward here, thanks for your continued academic stimulation,

Steve

perhaps you'll find this interesting

http://cancerres.aacrjournals.org/content/73/7/2059

Seems like every research team has their "pet" biomarker or factor that may predict future,so to speak. All here are aware of CEA but there may be other indicators as well that may be more pertinent